Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Core Insights - Inhibrx Biosciences, Inc. announced updates on its clinical trials for INBRX-106 and ozekibart, focusing on oncology therapeutics [1] INBRX-106 Clinical Trials - The Phase 2 portion of the INBRX-106 trial has recruited 46 out of 60 patients, with expected completion of enrollment in Q1 2026 [2] - The trial targets patients with unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) who have not received prior systemic therapy and have tumor PD-L1 CPS expression ≥ 20 [2] - Primary endpoint is overall response rate, with secondary endpoints including duration of response, progression-free survival, and safety [2] - Data maturity for HNSCC and NSCLC trials is anticipated in H2 2026 to assess the efficacy of INBRX-106 in combination with Keytruda [4] Ozekibart Clinical Trials - Enrollment for the Phase 1/2 trial of ozekibart in combination with FOLFIRI for advanced colorectal cancer has been completed with 44 patients [5] - Ozekibart showed good tolerability and durable responses, with progression-free survival data expected in Q2 2026 [5] - The trial for ozekibart in combination with irinotecan and temozolomide for Ewing sarcoma is expected to complete enrollment in Q2 2026, with plans to discuss accelerated approval with the FDA in H2 2026 if trends continue [6] Product Descriptions - INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, currently being investigated for HNSCC and NSCLC [7] - Ozekibart is a tetravalent DR5 agonist antibody designed to induce tumor-biased cell death, with a BLA filing expected in early Q2 2026 [8] Company Overview - Inhibrx Biosciences focuses on developing a pipeline of novel biologic therapeutic candidates using advanced protein engineering methods [9]